Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 3
2021 5
2022 5
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing.
Davi F, Langerak AW, de Septenville AL, Kolijn PM, Hengeveld PJ, Chatzidimitriou A, Bonfiglio S, Sutton LA, Rosenquist R, Ghia P, Stamatopoulos K; ERIC, the European Research Initiative on CLL, and the EuroClonality-NGS Working Group. Davi F, et al. Among authors: kolijn pm. Leukemia. 2020 Oct;34(10):2545-2551. doi: 10.1038/s41375-020-0923-9. Epub 2020 Jun 19. Leukemia. 2020. PMID: 32561841 Free PMC article. Review.
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Hengeveld PJ, van der Klift MY, Kolijn PM, Davi F, Kavelaars FG, de Jonge E, Robrecht S, Assmann JLJC, van der Straten L, Ritgen M, Westerweel PE, Fischer K, Goede V, Hallek M, Levin MD, Langerak AW. Hengeveld PJ, et al. Among authors: kolijn pm. Blood. 2023 Feb 2;141(5):519-528. doi: 10.1182/blood.2022017411. Blood. 2023. PMID: 36084320 Free article.
Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110.
Hengeveld PJ, Ertem YE, Dubois JMN, Mellink CHM, van der Kevie-Kersemaekers AM, Evers LM, Heezen K, Kolijn PM, Mook ORF, Motazacker MM, Nasserinejad K, Kersting S, Westerweel PE, Niemann CU, Kater AP, Langerak AW, Levin MD. Hengeveld PJ, et al. Among authors: kolijn pm. Leukemia. 2022 Jul;36(7):1935-1938. doi: 10.1038/s41375-022-01600-6. Epub 2022 May 18. Leukemia. 2022. PMID: 35585140 No abstract available.
T and NK Cells in IL2RG-Deficient Patient 50 Years After Hematopoietic Stem Cell Transplantation.
Melsen JE, van Ostaijen-Ten Dam MM, van den Akker EB, Welters MJP, Heezen KC, Pico-Knijnenburg I, Kolijn PM, Bredius RGM, van Doorn R, Langerak AW, Schilham MW, Lankester AC. Melsen JE, et al. Among authors: kolijn pm. J Clin Immunol. 2022 Aug;42(6):1205-1222. doi: 10.1007/s10875-022-01279-5. Epub 2022 May 9. J Clin Immunol. 2022. PMID: 35527320 Free PMC article.
High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis.
Kolijn PM, Hosnijeh FS, Späth F, Hengeveld PJ, Agathangelidis A, Saleh M, Casabonne D, Benavente Y, Jerkeman M, Agudo A, Barricarte A, Besson C, Sánchez MJ, Chirlaque MD, Masala G, Sacerdote C, Grioni S, Schulze MB, Nieters A, Engelfriet P, Hultdin M, McKay JD, Vermeulen RCH, Langerak AW. Kolijn PM, et al. Blood. 2022 Mar 10;139(10):1557-1563. doi: 10.1182/blood.2021012890. Blood. 2022. PMID: 34662377 Free PMC article.
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Hengeveld PJ, Schilperoord-Vermeulen J, van der Klift MY, Dubois JMN, Kolijn PM, Kavelaars FG, Rijken M, Dobber JA, Nasserinejad K, Kersting S, Westerweel PE, Kater AP, Langerak AW, Levin MD. Hengeveld PJ, et al. Among authors: kolijn pm. Blood Cancer J. 2023 Jul 4;13(1):102. doi: 10.1038/s41408-023-00870-2. Blood Cancer J. 2023. PMID: 37400508 Free PMC article. No abstract available.
20 results